Theravance Biopharma
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $19,990 | $26,195 | $15,388 | $18,754 |
Gross Profit | 11,878 | 15,705 | 3,936 | 18,754 |
EBITDA | -1,907 | -2,316 | -14,021 | -7,601 |
EBIT | -2,316 | -2,725 | -14,434 | -8,296 |
Net Income | 3,615 | 54,835 | -13,579 | -15,527 |
Net Change In Cash | 19,990 | 26,195 | 15,388 | 18,754 |
Free Cash Flow | -6,508 | 208,040 | 43,039 | -1,092 |
Cash | 329,680 | 281,927 | 110,614 | 37,797 |
Basic Shares | 51,908 | 50,726 | 49,706 | 49,306 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $64,381 | $57,424 | $51,346 | $55,311 |
Gross Profit | 64,381 | 16,803 | -12,046 | -138,346 |
EBITDA | -38,453 | -51,648 | -76,084 | -232,830 |
EBIT | -42,068 | -53,649 | -79,119 | -237,642 |
Net Income | -56,418 | -55,193 | 872,132 | -199,426 |
Net Change In Cash | 64,381 | 57,424 | 51,346 | 55,311 |
Cost of Revenue | 208,212 | 8,496 | ||
Free Cash Flow | -11,867 | -29,485 | -187,563 | -211,264 |
Cash | 37,797 | 39,545 | 298,172 | 89,959 |
Basic Shares | 48,847 | 55,303 | 73,591 | 69,461 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | $0.04 |
2025-06-30 | -$0.08 |
2025-03-31 | -$0.17 |
